Physician profile
Manal Alhakim
NPI 1699055566
$1,567.74
in general payments reported to CMS, 2019-2025
24 companies · $720 in 2025
The $720 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.05 · 2022: $47.96 · 2023: $371 · 2024: $400 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.88 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $285.25 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $224.75 | 2023-2024 | (7999) Src Undivided, (Ak6) Vest Therapy |
| Insulet Corporation | $175.03 | 2024-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $98.43 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $72.00 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $60.96 | 2024-2025 | |
| Madrigal Pharmaceuticals | $59.14 | 2025 | Rezdiffra |
| Medtronic, INC. | $57.91 | 2024-2025 | Minimed 780g |
| Actelion Pharmaceuticals US, INC. | $57.49 | 2023 | Uptravi, Opsumit |
| Novo Nordisk INC | $57.22 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $55.39 | 2023 | |
| Astellas Pharma US INC | $51.99 | 2025 | Veozah, Cresemba |
| Mannkind Corporation | $48.69 | 2024-2025 | |
| Abbott Laboratories | $42.97 | 2023-2025 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $38.95 | 2025 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.65 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $28.05 | 2019 | |
| Merck Sharp & Dohme LLC | $22.66 | 2024 | Keytruda |
| Mallinckrodt Hospital Products INC. | $19.34 | 2023 | Acthar |
| Radius Health, INC. | $16.94 | 2025 | Tymlos |
| La Jolla Pharmaceutical Company | $16.54 | 2024 | Giapreza |
| Dexcom, INC. | $15.13 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.09 | 2025 | Unithroid |
| Tandem Diabetes Care, INC. | $14.17 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manal Alhakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.